Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Cardiff Oncology, Inc. Common Stock

CRDF

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Last trade $0.8499
Day change +$0.0022 (+0.26%)
Day range $0.788 – $0.905
Volume 1,659,079
Market cap $66M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$66.13M
Price / earnings
—
Price / book
2.35×
Price / sales
118.29×
EV / sales
96.72×
EV / EBITDA
-1.38×

Profitability

Earnings per share
-$0.48
Return on assets
-103.45%
Return on equity
-134.06%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.21×
Quick ratio
4.21×
Cash ratio
1.45×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$39.94M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CRDF, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$171K$104K$41K$243K$120K$121K$109K$151K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$171K$104K$41K$243K$120K$121K$109K$151K
Selling, general and administrative$4.36M$3.8M$6.13M$3M$3.9M$3.32M$4.01M$3.01M
Research and development$5.03M$5.92M$6.77M$5.08M$8.2M$11.58M$10.48M$9.71M
Total operating expenses$9.39M$9.72M$12.89M$8.07M$12.09M$14.9M$14.49M$12.72M
Operating income-$9.22M-$9.62M-$12.85M-$7.83M-$11.97M-$14.78M-$14.38M-$12.57M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$8.86M-$9.23M-$12.35M-$7.22M-$11.26M-$13.94M-$13.43M-$11.79M
Income taxes$0$0$0$0$0$0$0$0
Net income-$8.86M-$9.23M-$12.35M-$7.22M-$11.26M-$13.94M-$13.43M-$11.79M
Net income attributable to common shareholders-$8.86M-$9.24M-$12.35M-$7.22M-$11.26M-$13.95M-$13.44M-$11.79M
EBITDA-$9.13M-$9.53M-$12.76M-$7.74M-$11.89M-$14.68M-$14.29M-$12.48M
Basic earnings per share-$0.12-$0.14-$0.18-$0.11-$0.17-$0.21-$0.20-$0.22
Diluted earnings per share-$0.12-$0.14-$0.18-$0.11-$0.17-$0.21-$0.20-$0.22

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Cardiff Oncology to Participate in the UBS Global Biopharma Conference

Cardiff Oncology announced that company management will present at the UBS Global Biopharma Conference on November 16-17, 2026. CEO Mani Mohindru will participate in a fireside chat and 1x1 investor meetings. The company is advancing onvansertib, a PLK1 inhibitor in Phase 2 trials for RAS-mutated mCRC treatment.

GlobeNewswire Inc.

Cardiff Oncology to Participate in September 2026 Conferences

Cardiff Oncology announced that Dr. Mani Mohindru will present at two upcoming conferences in September 2026, discussing the company's PLK1 inhibitor onvansertib for RAS-mutated metastatic colorectal cancer treatment. The company is advancing its lead asset through Phase 2 trials with positive data previously presented at ASCO.

GlobeNewswire Inc.

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

Cardiff Oncology announced updated Phase 2 CRDF-004 data for onvansertib, a PLK1 inhibitor, will be presented at ASCO 2026 on June 2, 2026, with an investor webcast scheduled for June 3, 2026. The company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational Phase 3 trial for first-line RAS-mutated metastatic colorectal cancer, following positive dose-dependent improvements in response rates and progression-free survival.

GlobeNewswire Inc.

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Cardiff Oncology announced preclinical data showing its PLK1 inhibitor onvansertib enhanced antitumor activity of trastuzumab deruxtecan and reversed resistance in therapy-resistant HER2-low breast cancer models. The findings will be presented at the AACR Annual Meeting in April 2026. Onvansertib is currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer and other cancers.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 20, 20191-for-6reverse split
Jun 4, 20181-for-12reverse split